SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on the predicting feature of hOCT1 gene expression in terms of therapeutic response to imatinib in CML patients [104,105,106], the same group investigated the efficacy of upregulating hOCT1 by other NRs [107].